Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment

Laura R Steeples,1,2 Sasa Pockar,1 Nicholas P Jones,1,2 Inês Leal3,4 1Manchester Royal Eye Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; 2Faculty of Biology, Medicine & Health, University of Manchester, Ma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Steeples LR, Pockar S, Jones NP, Leal I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	fluocinolone acetonide implant non-infectious uveitis posterior segment efficacy safety Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/67b04b7854c04221a490dc443f4e7674
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:67b04b7854c04221a490dc443f4e7674
record_format	dspace
spelling	oai:doaj.org-article:67b04b7854c04221a490dc443f4e76742021-12-02T14:36:19ZEvaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment1177-5483https://doaj.org/article/67b04b7854c04221a490dc443f4e76742021-04-01T00:00:00Zhttps://www.dovepress.com/evaluating-the-safety-efficacy-and-patient-acceptability-of-intravitre-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Laura R Steeples,1,2 Sasa Pockar,1 Nicholas P Jones,1,2 Inês Leal3,4 1Manchester Royal Eye Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; 2Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK; 3Ophthalmology Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal; 4Centro de Estudos das Ciências da Visão, Faculdade de Medicina, Universidade de Lisboa, Lisbon, PortugalCorrespondence: Laura R Steeples Email Laura.steeples@mft.nhs.ukAbstract: Long-acting, slow-release injectable fluocinolone intravitreal implants have been approved for the treatment of non-infectious uveitis affecting the posterior segment. We summarise the development of intravitreal fluocinolone implants and discuss the technology including pharmacokinetics. We conducted a systematic review of evidence for the efficacy, safety and patient acceptability of fluocinolone 0.18 mg and 0.19 mg injectable implants. We summarise evidence from the pivotal phase 3 studies that lead to the approval of these implants and evaluate real-world including disease-specific evidence. Safety including injection-related events and long-term adverse events is presented.Keywords: fluocinolone acetonide implant, non-infectious uveitis, posterior segment, efficacy, safetySteeples LRPockar SJones NPLeal IDove Medical Pressarticlefluocinolone acetonide implantnon-infectious uveitisposterior segmentefficacysafetyOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 1433-1442 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	fluocinolone acetonide implant non-infectious uveitis posterior segment efficacy safety Ophthalmology RE1-994
spellingShingle	fluocinolone acetonide implant non-infectious uveitis posterior segment efficacy safety Ophthalmology RE1-994 Steeples LR Pockar S Jones NP Leal I Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment
description	Laura R Steeples,1,2 Sasa Pockar,1 Nicholas P Jones,1,2 Inês Leal3,4 1Manchester Royal Eye Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; 2Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK; 3Ophthalmology Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal; 4Centro de Estudos das Ciências da Visão, Faculdade de Medicina, Universidade de Lisboa, Lisbon, PortugalCorrespondence: Laura R Steeples Email Laura.steeples@mft.nhs.ukAbstract: Long-acting, slow-release injectable fluocinolone intravitreal implants have been approved for the treatment of non-infectious uveitis affecting the posterior segment. We summarise the development of intravitreal fluocinolone implants and discuss the technology including pharmacokinetics. We conducted a systematic review of evidence for the efficacy, safety and patient acceptability of fluocinolone 0.18 mg and 0.19 mg injectable implants. We summarise evidence from the pivotal phase 3 studies that lead to the approval of these implants and evaluate real-world including disease-specific evidence. Safety including injection-related events and long-term adverse events is presented.Keywords: fluocinolone acetonide implant, non-infectious uveitis, posterior segment, efficacy, safety
format	article
author	Steeples LR Pockar S Jones NP Leal I
author_facet	Steeples LR Pockar S Jones NP Leal I
author_sort	Steeples LR
title	Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment
title_short	Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment
title_full	Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment
title_fullStr	Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment
title_full_unstemmed	Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment
title_sort	evaluating the safety, efficacy and patient acceptability of intravitreal fluocinolone acetonide (0.2mcg/day) implant in the treatment of non-infectious uveitis affecting the posterior segment
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/67b04b7854c04221a490dc443f4e7674
work_keys_str_mv	AT steepleslr evaluatingthesafetyefficacyandpatientacceptabilityofintravitrealfluocinoloneacetonide02mcgdayimplantinthetreatmentofnoninfectiousuveitisaffectingtheposteriorsegment AT pockars evaluatingthesafetyefficacyandpatientacceptabilityofintravitrealfluocinoloneacetonide02mcgdayimplantinthetreatmentofnoninfectiousuveitisaffectingtheposteriorsegment AT jonesnp evaluatingthesafetyefficacyandpatientacceptabilityofintravitrealfluocinoloneacetonide02mcgdayimplantinthetreatmentofnoninfectiousuveitisaffectingtheposteriorsegment AT leali evaluatingthesafetyefficacyandpatientacceptabilityofintravitrealfluocinoloneacetonide02mcgdayimplantinthetreatmentofnoninfectiousuveitisaffectingtheposteriorsegment
_version_	1718391010425307136

Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment

Ejemplares similares